1047 El Camino Real
8 articles about NuMedii
NuMedii Announces Creation of World's First Single-Cell Sequencing Atlas for Idiopathic Pulmonary Fibrosis by its Collaborators
NuMedii, Inc., a data-driven drug discovery company, today announced the availability of the world's first single-cell sequencing atlas for idiopathic pulmonary fibrosis (IPF) that was the result of a strategic research collaboration including the Yale School of Medicine, Baylor College of Medicine, Brigham and Women's Hospital, and NuMedii.
NuMedii, Inc. today announced a new partnership with a drug delivery company to develop new therapeutics for ulcerative colitis
NuMedii Announces Research Collaboration With Leading Academic Research Institution to Explore New Targets and Therapeutics for Pancreatitis
The collaboration brings together deep clinical expertise with NuMedii's Artificial Intelligence Drug Discovery technology, which will enable the discovery of novel targets and precision drug candidates for both acute and chronic forms of the disease.
NuMedii, Inc., today announced the appointment of Heather Arnett, Ph.D., as Vice President, Research.
NuMedii Announces Strategic Research Collaboration with Two Leading Academic Research Institutions Utilizing Single-Cell Sequencing to Identify Precision Therapeutics for IPF
NuMedii, Inc., today announced the formation of a strategic research collaboration with Yale School of Medicine and Brigham and Women's Hospital
The newly formed Board of Advisors will provide deep scientific and clinical expertise to the company as it discovers and advances new treatments for IPF based on NuMedii's AIDD technology.
NuMedii Announces New Partnership To Discover And Advance New Treatments For Idiopathic Pulmonary Fibrosis